Microbiology Series 2012 – Part 1
We are pleased to present the first three articles in our Microbiology series on Rapid Microbiological Methods written by Dr. Michael J. Miller...
List view / Grid view
We are pleased to present the first three articles in our Microbiology series on Rapid Microbiological Methods written by Dr. Michael J. Miller...
18 September 2012 | By B&W Tek
In this free one hour instructional webinar you will learn how handheld Raman reduces costs and improves efficiency, the move to mandatory 100% testing of incoming raw materials, and recent developments in handheld Raman technology...
3 September 2012 | By David Cook & James Milligan, AstraZeneca
Ensuring patient safety during clinical trials is of paramount consideration with stringent monitoring built into trials (and beyond) and the design and interpretation of safety outcomes subject to a large amount of regulation. As a result, it is rare for clinical trials to produce extreme adverse drug reactions but it…
In the laboratory, weighing is only one step of a whole analysis chain in drug discovery and quality control; however it strongly influences the overall quality and integrity of the final result. Proper weighing is thus essential to ensure continuous adherence to predefined process requirements and to avoid a frequent…
10 July 2012 | By Anthony Mitchell Davies & Anne Marie Byrne, Department of Clinical Medicine Trinity College Dublin; Holger Erfle, BIOQUANT-Zentrum Ruprecht-Karls-Universität Heidelberg; Graham Donnelly, Rita Murray & Peadar MacGabhann, Biocroi Ltd
One of the major limitations of performing large-scale High Content Analysis (HCA) screens is reagent cost, indeed this fact has been a key driver in the development of assay size reduction strategies here at The Irish National Centre for High Content Screening and Analysis at Trinity College’s Department of Medicine.…
Foster Jordan, Corporate Senior Vice President, Endotoxin and Microbial Detection, Charles River discusses QC testing and why it is so important in the pharmaceutical industry.
2 July 2012 | By DeltaNu
PHARMA•ID™ is a palm-sized, easy to use Raman spectrometer identifies and validates excipients and active pharmaceutical ingredients (API) wherever testing is needed.
Changes in ISO 14644-1 to improve confidence in quality for critical life-science applications. Tony Harrison, UK Subject Matter Expert to ISO TC209 Working Group.
26 April 2012 | By Clare Strachan, Senior Lecturer Pharmaceutical Sciences, School of Pharmacy, University of Otago
The use of Raman spectroscopy in pharmaceuticals has grown enormously since its appearance on the scene in the 1980s1-4. While typical Raman spectroscopy setups are able to provide chemical and physicochemical information about the sample on the bulk level, most solid samples in the pharmaceutical setting may not be assumed…
9 February 2012 | By HACH LANGE
This pharma webinar presents experts in the fields of monitoring and compliance and pharmaceutical water and cleanroom facility standards.
3 November 2011 | By Renishaw
Raman spectroscopy came under the spotlight recently at the Natural History Museum in London...
27 October 2011 | By Mike Claybourn, Raman Product Manager, HORIBA Scientific, 16 rue du Canal, 91160 Longjumeau France
Raman spectroscopy, a technology that has a long pedigree of success in Pharmaceutical Development...
In this Rapid Methods supplement: A regulators view; Nucleic acid and gene amplification-based technologies; Challenges and strategies for application in the pharmaceutical industry...
In this Raman supplement: Solid state transformations of APIS during manufacturing by Raman analysis of pharmaceutical molecules and dosage forms; Detection, determination of chemical composition and chemical profiling of counterfeit medicines...
31 August 2011 | By Jerome Giovannoni and J.M. Peltier, Novartis
The constant growth of compound collections, combined with screening efforts on more challenging targets, is creating an increasing demand for quality control in order to ensure the integrity of the compound solutions being tested. This is true throughout the early drug discovery pipeline, from hit identification to lead nomination. Novartis…